2.05
Perspective Therapeutics Inc stock is traded at $2.05, with a volume of 1.57M.
It is up +4.59% in the last 24 hours and down -26.26% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$1.96
Open:
$2.04
24h Volume:
1.57M
Relative Volume:
2.03
Market Cap:
$145.14M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-11.95
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
-9.69%
1M Performance:
-26.26%
6M Performance:
-84.48%
1Y Performance:
-85.96%
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CATX
Perspective Therapeutics Inc
|
2.05 | 145.14M | 6.96M | -46.51M | -37.99M | -0.1716 |
![]()
ABT
Abbott Laboratories
|
131.93 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-25 | Initiated | H.C. Wainwright | Buy |
Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
Oct-24-24 | Initiated | UBS | Buy |
Oct-01-24 | Initiated | Wedbush | Outperform |
Sep-25-24 | Initiated | Truist | Buy |
Jul-25-24 | Initiated | BofA Securities | Buy |
May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Australia
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com UK
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World
Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times
Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan
Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World
Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World
HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World
Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com
Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Reports 2024 Earnings and Clinical Progress - TipRanks
Perspective Therapeutics Inc (CATX) Reports Annual EPS Loss of $1.23, Revenue at $1.5 Million, Surpassing Estimates - GuruFocus.com
Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026 - Marketscreener.com
Perspective Therapeutics Secures 2-Year Runway with $227M Cash, Advances Cancer Trials - Stock Titan
CATX stock touches 52-week low at $2.31 amid market fluctuations - Investing.com
What is HC Wainwright’s Forecast for CATX FY2025 Earnings? - Defense World
Brachytherapy Market Expected to Reach USD 1.5 Billion by 2031 | - openPR
HC Wainwright Reiterates “Buy” Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush - Defense World
Perspective Flat on New Drug Trials - Baystreet.ca
Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy - Marketscreener.com
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - Marketscreener.com
Perspective Therapeutics, Inc. Initiates First Patient Dosing in Phase 1/2a Trial of [212Pb]VMT01 for Melanoma Treatment - Nasdaq
Breakthrough Melanoma Treatment: New Alpha Therapy Combined With Opdivo Shows Promise - Stock Titan
Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register
Analysts Issue Forecasts for CATX Q4 Earnings - Defense World
HC Wainwright Initiates Coverage on Perspective Therapeutics (NYSE:CATX) - Defense World
Dyne Therapeutics Inc (DYN): A New Perspective - Stocks Register
Brookline Capital Management Estimates CATX FY2024 Earnings - The AM Reporter
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
HC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation - Nasdaq
Brokers Set Expectations for CATX FY2024 Earnings - Defense World
Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Brookline Capital Management - Defense World
Perspective Therapeutics at Barclays Healthcare: Radiopharmaceutical Innovations By Investing.com - Investing.com Canada
Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target -March 10, 2025 at 08:33 am EDT - Marketscreener.com
Rhumbline Advisers Has $303,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of “Buy” by Brokerages - Defense World
Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Scotiabank - Defense World
Perspective Therapeutics (NYSE:CATX) Upgraded at Lifesci Capital - Defense World
Scotiabank Initiates Coverage of Perspective Therapeutics (CATX) with Sector Outperform Recommendation - Nasdaq
Scotiabank starts Perspective Therapeutics with Sector Outperform By Investing.com - Investing.com South Africa
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cap:
|
Volume (24h):